Caregen Co.Ltd (214370) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of Caregen Co.Ltd stock ₩5,414, price ₩28,050, that is 80.7% below the price, quality 71 out of 100. Rating: strongly overvalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Caregen Co.Ltd
214370 · KQFar too expensive (fair value 81% below the price) and falling price, but solid company: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 20, 2026.
How to read this chart
60‑month range ₩9,606 – ₩149,635 · fair‑value band ₩3,672 – ₩7,690 · the ₩28,050 price screens above the ₩5,414 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 20, 2026.
Every Wednesday you see whether Caregen Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands.
Show moreShow less
It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names.
The company's products are used in anti-aging, anti-pigmentation, anti-hair loss, anti-inflammation, and other skin troubles, as well as blood sugar control, baby skin care, and acute muscle pain applications.
In addition, its products in pipeline include pharmaceuticals in the areas of wet and dry macular degeneration, diabetic retinopathy, cataract, hyperhidrosis, pain relief, obesity, psoriasis, scar, arthritis, rhinitis, anti-virus, and Covid-19 treatment; and medical devices for face beauty treatment, scalp and hair improvement, body care, arthritis, and new face beauty treatment.
Further, the company is developing cosmeceutical produts for anti-wrinkle, whitening, sun block, atopic dermatitis care, particulate matter inhibition, double chin removal, dark circle care, reduction of cellulite, sebum secretion control, and pore tightening applications; and food supplements in the areas of hangover cure, cholesterol control, and body fat lipolysis.
Caregen Co., Ltd. was founded in 2001 and is based in Anyang-si, South Korea.
Stock analysis
Caregen Co.Ltd (214370) currently trades at ₩28,050, while our model-based Fair Value estimate is ₩5,414, 81% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of ₩8,286 per share, and 0 of the 25 models we run sit above the ₩28,050 price.
Bear case: the Asset-Based group reads lowest at ₩1,317, and 25 of the 25 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₩3,672 (bear) to ₩7,690 (bull), the price of ₩28,050 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Caregen Co.Ltd reported revenue of 72.8B KRW in FY2025 versus 59.1B KRW in FY2021, a compound +5.4%/yr. Reported net income was 20.1B KRW in FY2025, compounding −5.6%/yr from FY2021.
Key figures
Market cap 1.4T KRW (≈ $1.0B) Small · P/S ratio 20.2 · Dividend yield 2.1% · Net margin 39.6% · Return on equity 1,456% · Return on assets (EBIT) 13.3% (5-year average) · Operating margin 46.3% · Revenue (TTM) 65.0B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 82 out of 100 (low confidence).
What moves the price
The share trades about 81% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −22% fair-value upside, at −81%, 214370 screens richer than that median.
Fair Value models
All 25 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
214370 screens overvalued: fair value 81% below the price. Compare with ST Pharm Co →
Compare Caregen Co.Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 57 stocks
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on assets by industry
- Fair value gap by industry
- PEG screener for stocks with fair value
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Huons Global Co 084110 | ₩19,530 | ₩47,019 | +141% | vs 214370 |
| VIKRAMTH VIKRAMTH | ₹325.05 | ₹352.17 | +8% | vs 214370 |
| DongKook Pharmaceutical Co 086450 | ₩26,700 | ₩28,372 | +6% | vs 214370 |
| ST Pharm Co 237690 | ₩75,000 | ₩61,182 | −18% | vs 214370 |
| Vivozon Pharmaceutical Co 082800 | ₩2,800 | ₩2,179 | −22% | vs 214370 |
| Oscotec Inc 039200 | ₩32,400 | ₩21,262 | −34% | vs 214370 |
| NatureCell Co 007390 | ₩21,300 | ₩11,176 | −48% | vs 214370 |
| Mezzion Pharma Co 140410 | ₩61,700 | ₩31,450 | −49% | vs 214370 |
| BINEX Co 053030 | ₩7,010 | ₩1,844 | −74% | vs 214370 |
| SHUKRAPHAR SHUKRAPHAR | ₹82.22 | ₹9.14 | −89% | vs 214370 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Caregen Co.Ltd (214370) overvalued or undervalued?
What is the fair value of 214370?
What is the quality score of 214370?
What is the price target for Caregen Co.Ltd (214370)?
What is the Caregen Co.Ltd stock forecast for 2026?
What is the revenue of Caregen Co.Ltd (214370)?
Does Caregen Co.Ltd pay a dividend?
How much is the dividend of Caregen Co.Ltd (214370)?
What growth is priced into Caregen Co.Ltd (214370)?
What discount rate (WACC) does the fair value of 214370 use?
What is a reverse DCF?
How much growth has Caregen Co.Ltd (214370) delivered so far?
How fast is the sector of Caregen Co.Ltd (214370) growing?
What is the free cash flow yield of Caregen Co.Ltd (214370)?
What is the intrinsic value of Caregen Co.Ltd (214370)?
Is Caregen Co.Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 214370?
How much is Caregen Co.Ltd worth?
What do the bullish and bearish scenarios say about 214370?
How far is 214370 from its 52-week high?
Which stocks are comparable to Caregen Co.Ltd?
Is Caregen Co.Ltd stock attractive at the current price?
How is the fair value of 214370 calculated?
Is it still worth investing in stocks now?
What is the share price of Caregen Co.Ltd (214370)?
What should I pay attention to with Caregen Co.Ltd right now?
Key figures of Caregen Co.Ltd
How large is the market capitalisation of Caregen Co.Ltd (214370)?
What is the P/S ratio of Caregen Co.Ltd (214370)?
What is the dividend yield of Caregen Co.Ltd (214370)?
What is the net margin of Caregen Co.Ltd (214370)?
What is the return on equity of Caregen Co.Ltd (214370)?
What is the EBIT return on assets of Caregen Co.Ltd (214370)?
What is the operating margin of Caregen Co.Ltd (214370)?
How fast is revenue growing at Caregen Co.Ltd (214370)?
How fast are earnings growing at Caregen Co.Ltd (214370)?
Watch Caregen Co.Ltd in the live analysis
One click puts Caregen Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.